

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for February 2026

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp Bilastine Oral Solution	Blexten	BILASTINE	2.5 mg/mL	solution (oral)	02448262
Juno Pharma Canada Inc.	Eptifibatide Injection	Integrilin	EPTIFIBATIDE	0.75 mg/mL	solution (intravenous)	02540819
Juno Pharma Canada Inc.	Eptifibatide Injection	Integrilin	EPTIFIBATIDE	2 mg/mL	solution (intravenous)	02540827
Jamp Pharma Corporation	Jamp Doxepin	Sinequan	DOXEPIN HCL	75 mg	capsule	02559285
Jamp Pharma Corporation	Jamp Doxepin	Sinequan	DOXEPIN HCL	100 mg	capsule	02559293
Jamp Pharma Corporation	Jamp Enzalutamide	Xtandi	ENZALUTAMIDE	40 mg	capsule	02515229